Profesionales médicos

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estado, etc.

1. Long-Term Observational Extension of Participants in CREST-2Trial

   Scottsdale/Phoenix, Ariz.

   The purpose of this Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial study is to assess post-procedural efficiency of carotid endarterectomy and carotid stenting.

2. A Study of Immune-Mediated Activation of Astrocytes in Healthy Volunteers

   Rochester, Minn.

   The purpose of this study is to characterize the astrocyte response to various inflammatory drivers in the presence of innate immune cells collected from healthy subjects. We will identify innate immune cell populations that contribute to astrocyte reactivity and elucidate the mechanisms responsible for altering the transcriptional and translational profile of astrocytes.

3. A Study to Test Concussion Return to Baseline after Elective Craniotomy Procedure

   Jacksonville, Fla.

   The purpose of this study is to determine return to baseline (RTB) period after an elective craniotomy procedure using the ImPACT testing assessment.

4. A Multimodal Monitoring (MMM) Computer to Detect Physiologic Trends in Data in Neurointensive Care Unit Patients

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to identify important physiologic trends in bedside ICU data such as cerebral perfusion pressure (CPP), intracranial pressure (ICP) using a bedside “Multimodal monitoring” (MMM) computer which utilizes ICM+ Cambridge software.

5. A Study to Review Magnetic Resonance Imaging in Patients with Epilepsy

   Rochester, Minn.

   The primary purpose of this study is to compare the diagnostic utility of 7T MRI versus 3T MRI in the detection of subtle epileptogenic lesions in the brain.

6. A Study to Evaluate Sleep for Stroke Management and Recovery

   Rochester, Minn.

   The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.

7. A Study to Evaluate the Use of a Smartphone App for Stroke Patients with Obstructive Sleep Apnea

   Rochester, Minn.

   The purpose of this study is to evaluate the use of a smartphone app for stroke patients with obstructive sleep apnea in order to better use their positive airway pressure (PAP) therapy.

8. Pre-operative vs. Post-operative Radiosurgery for Metastatic Brain Tumors

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine whether there is an increase in the time of a first occurrence of either: local recurrence, leptomeningeal disease, or symptomatic radiation brain necrosis in patients with brain metastases who receive SRS prior to surgery as compared to patients who receive surgery prior to SRS.

    

9. Cerebrospinal Fluid (CSF) Biomarkers for Prediction of Dementia

   Rochester, Minn., Jacksonville, Fla.

   To further investigate biomarkers in CSF as possible predictors for mild cognitive impairment and dementia

10. A study to create and analyze a comprehensive longitudinal resource using testing results from those with genetic risk of Alzheimer's disease

    Scottsdale/Phoenix, Ariz.

    This study aims to establish, use, and extensively share a comprehensive longitudinal resource of genetic, non-genetic, and cognitive data, brain imaging and fluid biomarker measurements of amyloid-β (Aβ), tau pathophysiology, neurodegeneration, and inflammation (“A,T,N,I”), and biological samples to advance the study of cognitively unimpaired older adults at six levels of genetic risk for Alzheimer’s disease (AD) due to their apolipoprotein E (APOE) genotype, including understudied APOE2 and APOE4 homozygotes (HMs) at the lowest and highest risk and those APOE4 HMs and heterozygotes (HTs) who remain unimpaired at older ages due to unknown protective factors and spared pathophysiological effects despite their genetic risk.